Table 2.
Functional Status, Clinical Characteristics, and Treatment Information for Participants With Brain Metastasis and Participants With Non-CNS Metastasis
| Variable | Patients With Brain Metastasis (n = 61) | Patients With Non-CNS Metastasis (n = 41) |
|---|---|---|
| KPS, mean | 80 | 80 |
| 100 | 9 (14.8) | 12 (29.3) |
| 90 | 11 (18.0) | 3 (7.3) |
| 80 | 27 (44.3) | 14 (34.1) |
| 70 | 10 (16.4) | 10 (24.4) |
| ≤ 60 | 4 (6.5) | 2 (4.8) |
| Primary cancer location | ||
| Lung | 32 (52.5) | 8 (19.5) |
| Breast | 10 (16.4) | 6 (14.6) |
| Melanoma | 5 (8.2) | 4 (9.8) |
| Gynecological | 5 (8.2) | 3 (7.3) |
| Gastrointestinal | 3 (4.9) | 10 (24.4) |
| Renal | 2 (3.3) | 2 (4.9) |
| Prostate | 1 (1.6) | 5 (12.2) |
| Testicular | 1 (1.6) | 0 (0.0) |
| Other | 2 (3.3) | 3 (7.3) |
| No. of brain metastases, median | 2 | 0 |
| 1 | 26 (42.6) | NA |
| 2-3 | 19 (31.1) | NA |
| > 3 | 16 (26.2) | NA |
| Tumor location/hemisphere | ||
| Right | 14 (25.9) | NA |
| Left | 21 (38.9) | NA |
| Both | 19 (35.2) | NA |
| Cancer treatments | ||
| Surgery | 9 (14.8) | 2 (4.9) |
| Type of radiation | ||
| Focal | 51 (83.6) | NA |
| Whole brain | 8 (13.1) | NA |
| None | 2 (3.3) | NA |
| Past chemotherapy use | 23 (37.7) | 32 (78.0) |
| Current chemotherapy use | 8 (31.1) | 18 (43.9) |
| AED use | 10 (16.4) | NA |
| Corticosteroid use | 37 (60.7) | 8 (19.5) |
| Hormone therapy | 5 (8.2) | 7 (17.1) |
Abbreviations: AED, antiepileptic drug; NA, not available.
Age evaluated with ANOVA; sex, race, and education evaluated with Pearson chi-square test. Unless otherwise indicated, values are n (%).